On October 30, 2026, the US Department of Health and Human Services (HHS) said it will not take enforcement action against licensed pharmacies, federal facilities or licensed physicians that compound six peptides for individual patients with a prescription: BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon. It is a temporary policy, not an FDA approval, and it comes with strict conditions.

Update, November 12: doctors push back

On November 9, 2026, the American Medical Association adopted a policy urging HHS and the FDA to “immediately rescind” any move that makes it easier to compound unapproved peptides, and promised to push state boards toward enforcement against compounding pharmacies and telehealth sellers. The AMA did not name the HHS policy, and its vote has no legal force: the policy described below is still in place. Public comments on it (docket HHS-OASH-2026-0496) close on November 13, 2026.

Which peptides, and in what forms

The policy covers each peptide only in specific chemical forms and routes:

PeptideForms covered
BPC-157injection under the skin or into muscle, by mouth, on the skin
TB-500injection under the skin or into muscle
MOTS-cinjection under the skin or into muscle
KPVby mouth, on the skin
Semaxnasal spray or drops
Epitaloninjection, in intermittent courses

A seventh peptide reviewed in July, emideltide (better known as DSIP), was rejected by the FDA advisory committee and is not included.

What a pharmacy has to do

What has not changed

What it means if you use one of these peptides

A legal route now exists: a prescription from a clinician, filled by a state-licensed compounding pharmacy. You can ask the pharmacy for the certificate of analysis, which research sellers rarely provide in a verifiable form. Doses, however, are no better established than before.

For the math, note that a compounded product may arrive as a ready-made solution with the strength printed on the label in mg/mL. In that case there is nothing to mix: use the label concentration directly in our calculator or our units-to-mg guide. If it comes as powder, see our BAC water guide.

How to comment

HHS is taking public comments until November 13, 2026, in docket HHS-OASH-2026-0496 on Regulations.gov.

Sources

  1. Federal Register. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (October 30, 2026).
  2. Venable LLP. HHS announces interim enforcement discretion for section 503A compounding with certain peptide bulk drug substances (November 6, 2026; peptides, routes and conditions).
  3. BioXconomy. HHS greenlights sale of six unapproved peptides despite FDA guidance (November 4, 2026).
  4. NCPA. FDA grants enforcement discretion for compounding six peptides (October 29, 2026).
  5. Becker’s Hospital Review. New AMA policy targets unapproved peptide compounding (November 10, 2026).